News Release

Awards Given to Institutions and Physicians to Promote Excellence in Hemophilia Care

NEW YORK, November 4, 2002 - The National Hemophilia Foundation (NHF) today announced the sponsorship by Baxter Healthcare Corporation of the NHF Clinical Fellowship Program. The program will help to increase the number of clinicians who are dedicated to providing care to patients with bleeding disorders, like hemophilia, and prepare fellows for academic careers.

Baxter has pledged to fund the program with a gift of $2.125 million. The NHF fellowships will support training programs by institutions with established hemophilia treatment centers in the United States that are committed to training clinicians, as well as physicians interested in specializing in coagulation disorders.

"We're grateful that Baxter has recognized the importance of treatment centers and physicians specialized in hemophilia management," said Glenn Pierce, M.D., PhD., president, National Hemophilia Foundation. "By supporting this program, Baxter is making sure the future of hemophilia treatment is a bright one."

The introduction of the Clinical Fellowship Program comes at a time when a large number of hemophilia treatment center physicians are retiring or leaving the field. With this program, the NHF and Baxter hope to increase the number of skilled physicians who can provide comprehensive care for patients.

"Baxter is committed to the hemophilia community, not only through innovative treatments, but also through education," said Peter O'Malley, president, Baxter BioScience North America. "This program will encourage physicians to explore their interest in treating hemophilia, and they, in turn, will give care to the community."

Selection Criteria
To be eligible for grants, institutions must have well established hemophilia/ thrombophilia treatment centers with qualified clinical and research faculty, committed to the development of fellows. Candidates for fellowship grants must have a medical degree, pre-fellowship clinical training and an interest in bleeding disorders. The Fellowship Program will be ongoing for five years with funding awarded to institutions for up to two years.

About Hemophilia
Hemophilia is caused by the absence or severe deficiency of factor VIII, a protein in human blood critical for proper blood coagulation. It is estimated that more than 400,000 people are living with hemophilia worldwide (1). Patients can experience spontaneous, uncontrolled internal bleeding that often is associated with pain, chronic joint destruction and, if left untreated, death.

People with hemophilia infuse themselves with clotting factors on average three times a month, unless they are on a preventive regimen, in which case they could infuse multiple times per week. Barring other complications or disorders, clinicians today expect a near normal life expectancy for patients, provided they receive proper treatment.

About Baxter
Baxter Healthcare Corporation is the principal domestic operating business of Baxter International Inc. (NYSE: BAX). Baxter International Inc. is a global health care company that, through its subsidiaries, provides critical therapies for people with life-threatening conditions. Baxter's bioscience, medication delivery and renal products and services are used to treat patients with some of the most challenging medical conditions including cancer, hemophilia, immune deficiencies, infectious diseases, kidney disease and trauma.

(1) O'Mahoney Brian. Global Hemophilia Care Challenges and Opportunities. Plenary presentation at: XXV International Congress of the World Federation of Hemophilia; May 20, 2002: Seville, Spain.

FOR ADDITIONAL INFORMATION:

	Media Contacts: Deborah Spak, 847-948-2349 Nancy Lovre, 805-372-3543